Pharma & Healthcare
Global Nanobody Drug Market Research Report 2025
- Jun 06, 25
- ID: 290762
- Pages: 90
- Figures: 92
- Views: 10
The global market for Nanobody Drug was valued at US$ 615 million in the year 2024 and is projected to reach a revised size of US$ 2349 million by 2031, growing at a CAGR of 21.4% during the forecast period.
North American market for Nanobody Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nanobody Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nanobody Drug include Boehringer Ingelheim, Sanofi Company(Ablynx), Merck KGaA, Jerry Corning, Shenzhen Pregene Biopharma Co, Novamab, PersonGen, Nanjing Legend Biotechnology Co., Ltd., Taiwan Taisho Pharmaceutical, Yiteng Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nanobody Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanobody Drug.
The Nanobody Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nanobody Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nanobody Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Boehringer Ingelheim
Sanofi Company(Ablynx)
Merck KGaA
Jerry Corning
Shenzhen Pregene Biopharma Co
Novamab
PersonGen
Nanjing Legend Biotechnology Co., Ltd.
Taiwan Taisho Pharmaceutical
Yiteng Pharmaceutical
Beijing Shuoxing Biotechnology
Segment by Type
Monovalent Nanobodies
Multivalent Nanobodies
Fusion Nanobodies
Others
Segment by Application
Tumor Treatment
Immune Disease Treatment
Inflammatory Disease Treatment
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nanobody Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nanobody Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
North American market for Nanobody Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nanobody Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nanobody Drug include Boehringer Ingelheim, Sanofi Company(Ablynx), Merck KGaA, Jerry Corning, Shenzhen Pregene Biopharma Co, Novamab, PersonGen, Nanjing Legend Biotechnology Co., Ltd., Taiwan Taisho Pharmaceutical, Yiteng Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nanobody Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanobody Drug.
The Nanobody Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nanobody Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nanobody Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Boehringer Ingelheim
Sanofi Company(Ablynx)
Merck KGaA
Jerry Corning
Shenzhen Pregene Biopharma Co
Novamab
PersonGen
Nanjing Legend Biotechnology Co., Ltd.
Taiwan Taisho Pharmaceutical
Yiteng Pharmaceutical
Beijing Shuoxing Biotechnology
Segment by Type
Monovalent Nanobodies
Multivalent Nanobodies
Fusion Nanobodies
Others
Segment by Application
Tumor Treatment
Immune Disease Treatment
Inflammatory Disease Treatment
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nanobody Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nanobody Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Nanobody Drug Market Overview
1.1 Product Definition
1.2 Nanobody Drug by Type
1.2.1 Global Nanobody Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Monovalent Nanobodies
1.2.3 Multivalent Nanobodies
1.2.4 Fusion Nanobodies
1.2.5 Others
1.3 Nanobody Drug by Application
1.3.1 Global Nanobody Drug Market Value by Application (2024 VS 2031)
1.3.2 Tumor Treatment
1.3.3 Immune Disease Treatment
1.3.4 Inflammatory Disease Treatment
1.3.5 Others
1.4 Global Nanobody Drug Market Size Estimates and Forecasts
1.4.1 Global Nanobody Drug Revenue 2020-2031
1.4.2 Global Nanobody Drug Sales 2020-2031
1.4.3 Global Nanobody Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Nanobody Drug Market Competition by Manufacturers
2.1 Global Nanobody Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Nanobody Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Nanobody Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Nanobody Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nanobody Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nanobody Drug, Product Type & Application
2.7 Global Key Manufacturers of Nanobody Drug, Date of Enter into This Industry
2.8 Global Nanobody Drug Market Competitive Situation and Trends
2.8.1 Global Nanobody Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Nanobody Drug Players Market Share by Revenue
2.8.3 Global Nanobody Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nanobody Drug Market Scenario by Region
3.1 Global Nanobody Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Nanobody Drug Sales by Region: 2020-2031
3.2.1 Global Nanobody Drug Sales by Region: 2020-2025
3.2.2 Global Nanobody Drug Sales by Region: 2026-2031
3.3 Global Nanobody Drug Revenue by Region: 2020-2031
3.3.1 Global Nanobody Drug Revenue by Region: 2020-2025
3.3.2 Global Nanobody Drug Revenue by Region: 2026-2031
3.4 North America Nanobody Drug Market Facts & Figures by Country
3.4.1 North America Nanobody Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Nanobody Drug Sales by Country (2020-2031)
3.4.3 North America Nanobody Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nanobody Drug Market Facts & Figures by Country
3.5.1 Europe Nanobody Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Nanobody Drug Sales by Country (2020-2031)
3.5.3 Europe Nanobody Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nanobody Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Nanobody Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Nanobody Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Nanobody Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Nanobody Drug Market Facts & Figures by Country
3.7.1 Latin America Nanobody Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Nanobody Drug Sales by Country (2020-2031)
3.7.3 Latin America Nanobody Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Nanobody Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Nanobody Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Nanobody Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Nanobody Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nanobody Drug Sales by Type (2020-2031)
4.1.1 Global Nanobody Drug Sales by Type (2020-2025)
4.1.2 Global Nanobody Drug Sales by Type (2026-2031)
4.1.3 Global Nanobody Drug Sales Market Share by Type (2020-2031)
4.2 Global Nanobody Drug Revenue by Type (2020-2031)
4.2.1 Global Nanobody Drug Revenue by Type (2020-2025)
4.2.2 Global Nanobody Drug Revenue by Type (2026-2031)
4.2.3 Global Nanobody Drug Revenue Market Share by Type (2020-2031)
4.3 Global Nanobody Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Nanobody Drug Sales by Application (2020-2031)
5.1.1 Global Nanobody Drug Sales by Application (2020-2025)
5.1.2 Global Nanobody Drug Sales by Application (2026-2031)
5.1.3 Global Nanobody Drug Sales Market Share by Application (2020-2031)
5.2 Global Nanobody Drug Revenue by Application (2020-2031)
5.2.1 Global Nanobody Drug Revenue by Application (2020-2025)
5.2.2 Global Nanobody Drug Revenue by Application (2026-2031)
5.2.3 Global Nanobody Drug Revenue Market Share by Application (2020-2031)
5.3 Global Nanobody Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Company Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Boehringer Ingelheim Nanobody Drug Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 Sanofi Company(Ablynx)
6.2.1 Sanofi Company(Ablynx) Company Information
6.2.2 Sanofi Company(Ablynx) Description and Business Overview
6.2.3 Sanofi Company(Ablynx) Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Company(Ablynx) Nanobody Drug Product Portfolio
6.2.5 Sanofi Company(Ablynx) Recent Developments/Updates
6.3 Merck KGaA
6.3.1 Merck KGaA Company Information
6.3.2 Merck KGaA Description and Business Overview
6.3.3 Merck KGaA Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck KGaA Nanobody Drug Product Portfolio
6.3.5 Merck KGaA Recent Developments/Updates
6.4 Jerry Corning
6.4.1 Jerry Corning Company Information
6.4.2 Jerry Corning Description and Business Overview
6.4.3 Jerry Corning Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Jerry Corning Nanobody Drug Product Portfolio
6.4.5 Jerry Corning Recent Developments/Updates
6.5 Shenzhen Pregene Biopharma Co
6.5.1 Shenzhen Pregene Biopharma Co Company Information
6.5.2 Shenzhen Pregene Biopharma Co Description and Business Overview
6.5.3 Shenzhen Pregene Biopharma Co Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Shenzhen Pregene Biopharma Co Nanobody Drug Product Portfolio
6.5.5 Shenzhen Pregene Biopharma Co Recent Developments/Updates
6.6 Novamab
6.6.1 Novamab Company Information
6.6.2 Novamab Description and Business Overview
6.6.3 Novamab Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novamab Nanobody Drug Product Portfolio
6.6.5 Novamab Recent Developments/Updates
6.7 PersonGen
6.7.1 PersonGen Company Information
6.7.2 PersonGen Description and Business Overview
6.7.3 PersonGen Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 PersonGen Nanobody Drug Product Portfolio
6.7.5 PersonGen Recent Developments/Updates
6.8 Nanjing Legend Biotechnology Co., Ltd.
6.8.1 Nanjing Legend Biotechnology Co., Ltd. Company Information
6.8.2 Nanjing Legend Biotechnology Co., Ltd. Description and Business Overview
6.8.3 Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Product Portfolio
6.8.5 Nanjing Legend Biotechnology Co., Ltd. Recent Developments/Updates
6.9 Taiwan Taisho Pharmaceutical
6.9.1 Taiwan Taisho Pharmaceutical Company Information
6.9.2 Taiwan Taisho Pharmaceutical Description and Business Overview
6.9.3 Taiwan Taisho Pharmaceutical Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Taiwan Taisho Pharmaceutical Nanobody Drug Product Portfolio
6.9.5 Taiwan Taisho Pharmaceutical Recent Developments/Updates
6.10 Yiteng Pharmaceutical
6.10.1 Yiteng Pharmaceutical Company Information
6.10.2 Yiteng Pharmaceutical Description and Business Overview
6.10.3 Yiteng Pharmaceutical Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Yiteng Pharmaceutical Nanobody Drug Product Portfolio
6.10.5 Yiteng Pharmaceutical Recent Developments/Updates
6.11 Beijing Shuoxing Biotechnology
6.11.1 Beijing Shuoxing Biotechnology Company Information
6.11.2 Beijing Shuoxing Biotechnology Description and Business Overview
6.11.3 Beijing Shuoxing Biotechnology Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Beijing Shuoxing Biotechnology Nanobody Drug Product Portfolio
6.11.5 Beijing Shuoxing Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nanobody Drug Industry Chain Analysis
7.2 Nanobody Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nanobody Drug Production Mode & Process Analysis
7.4 Nanobody Drug Sales and Marketing
7.4.1 Nanobody Drug Sales Channels
7.4.2 Nanobody Drug Distributors
7.5 Nanobody Drug Customer Analysis
8 Nanobody Drug Market Dynamics
8.1 Nanobody Drug Industry Trends
8.2 Nanobody Drug Market Drivers
8.3 Nanobody Drug Market Challenges
8.4 Nanobody Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Nanobody Drug by Type
1.2.1 Global Nanobody Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Monovalent Nanobodies
1.2.3 Multivalent Nanobodies
1.2.4 Fusion Nanobodies
1.2.5 Others
1.3 Nanobody Drug by Application
1.3.1 Global Nanobody Drug Market Value by Application (2024 VS 2031)
1.3.2 Tumor Treatment
1.3.3 Immune Disease Treatment
1.3.4 Inflammatory Disease Treatment
1.3.5 Others
1.4 Global Nanobody Drug Market Size Estimates and Forecasts
1.4.1 Global Nanobody Drug Revenue 2020-2031
1.4.2 Global Nanobody Drug Sales 2020-2031
1.4.3 Global Nanobody Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Nanobody Drug Market Competition by Manufacturers
2.1 Global Nanobody Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Nanobody Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Nanobody Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Nanobody Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nanobody Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nanobody Drug, Product Type & Application
2.7 Global Key Manufacturers of Nanobody Drug, Date of Enter into This Industry
2.8 Global Nanobody Drug Market Competitive Situation and Trends
2.8.1 Global Nanobody Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Nanobody Drug Players Market Share by Revenue
2.8.3 Global Nanobody Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nanobody Drug Market Scenario by Region
3.1 Global Nanobody Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Nanobody Drug Sales by Region: 2020-2031
3.2.1 Global Nanobody Drug Sales by Region: 2020-2025
3.2.2 Global Nanobody Drug Sales by Region: 2026-2031
3.3 Global Nanobody Drug Revenue by Region: 2020-2031
3.3.1 Global Nanobody Drug Revenue by Region: 2020-2025
3.3.2 Global Nanobody Drug Revenue by Region: 2026-2031
3.4 North America Nanobody Drug Market Facts & Figures by Country
3.4.1 North America Nanobody Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Nanobody Drug Sales by Country (2020-2031)
3.4.3 North America Nanobody Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nanobody Drug Market Facts & Figures by Country
3.5.1 Europe Nanobody Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Nanobody Drug Sales by Country (2020-2031)
3.5.3 Europe Nanobody Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nanobody Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Nanobody Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Nanobody Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Nanobody Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Nanobody Drug Market Facts & Figures by Country
3.7.1 Latin America Nanobody Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Nanobody Drug Sales by Country (2020-2031)
3.7.3 Latin America Nanobody Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Nanobody Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Nanobody Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Nanobody Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Nanobody Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nanobody Drug Sales by Type (2020-2031)
4.1.1 Global Nanobody Drug Sales by Type (2020-2025)
4.1.2 Global Nanobody Drug Sales by Type (2026-2031)
4.1.3 Global Nanobody Drug Sales Market Share by Type (2020-2031)
4.2 Global Nanobody Drug Revenue by Type (2020-2031)
4.2.1 Global Nanobody Drug Revenue by Type (2020-2025)
4.2.2 Global Nanobody Drug Revenue by Type (2026-2031)
4.2.3 Global Nanobody Drug Revenue Market Share by Type (2020-2031)
4.3 Global Nanobody Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Nanobody Drug Sales by Application (2020-2031)
5.1.1 Global Nanobody Drug Sales by Application (2020-2025)
5.1.2 Global Nanobody Drug Sales by Application (2026-2031)
5.1.3 Global Nanobody Drug Sales Market Share by Application (2020-2031)
5.2 Global Nanobody Drug Revenue by Application (2020-2031)
5.2.1 Global Nanobody Drug Revenue by Application (2020-2025)
5.2.2 Global Nanobody Drug Revenue by Application (2026-2031)
5.2.3 Global Nanobody Drug Revenue Market Share by Application (2020-2031)
5.3 Global Nanobody Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Company Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Boehringer Ingelheim Nanobody Drug Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 Sanofi Company(Ablynx)
6.2.1 Sanofi Company(Ablynx) Company Information
6.2.2 Sanofi Company(Ablynx) Description and Business Overview
6.2.3 Sanofi Company(Ablynx) Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Company(Ablynx) Nanobody Drug Product Portfolio
6.2.5 Sanofi Company(Ablynx) Recent Developments/Updates
6.3 Merck KGaA
6.3.1 Merck KGaA Company Information
6.3.2 Merck KGaA Description and Business Overview
6.3.3 Merck KGaA Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck KGaA Nanobody Drug Product Portfolio
6.3.5 Merck KGaA Recent Developments/Updates
6.4 Jerry Corning
6.4.1 Jerry Corning Company Information
6.4.2 Jerry Corning Description and Business Overview
6.4.3 Jerry Corning Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Jerry Corning Nanobody Drug Product Portfolio
6.4.5 Jerry Corning Recent Developments/Updates
6.5 Shenzhen Pregene Biopharma Co
6.5.1 Shenzhen Pregene Biopharma Co Company Information
6.5.2 Shenzhen Pregene Biopharma Co Description and Business Overview
6.5.3 Shenzhen Pregene Biopharma Co Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Shenzhen Pregene Biopharma Co Nanobody Drug Product Portfolio
6.5.5 Shenzhen Pregene Biopharma Co Recent Developments/Updates
6.6 Novamab
6.6.1 Novamab Company Information
6.6.2 Novamab Description and Business Overview
6.6.3 Novamab Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novamab Nanobody Drug Product Portfolio
6.6.5 Novamab Recent Developments/Updates
6.7 PersonGen
6.7.1 PersonGen Company Information
6.7.2 PersonGen Description and Business Overview
6.7.3 PersonGen Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 PersonGen Nanobody Drug Product Portfolio
6.7.5 PersonGen Recent Developments/Updates
6.8 Nanjing Legend Biotechnology Co., Ltd.
6.8.1 Nanjing Legend Biotechnology Co., Ltd. Company Information
6.8.2 Nanjing Legend Biotechnology Co., Ltd. Description and Business Overview
6.8.3 Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Product Portfolio
6.8.5 Nanjing Legend Biotechnology Co., Ltd. Recent Developments/Updates
6.9 Taiwan Taisho Pharmaceutical
6.9.1 Taiwan Taisho Pharmaceutical Company Information
6.9.2 Taiwan Taisho Pharmaceutical Description and Business Overview
6.9.3 Taiwan Taisho Pharmaceutical Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Taiwan Taisho Pharmaceutical Nanobody Drug Product Portfolio
6.9.5 Taiwan Taisho Pharmaceutical Recent Developments/Updates
6.10 Yiteng Pharmaceutical
6.10.1 Yiteng Pharmaceutical Company Information
6.10.2 Yiteng Pharmaceutical Description and Business Overview
6.10.3 Yiteng Pharmaceutical Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Yiteng Pharmaceutical Nanobody Drug Product Portfolio
6.10.5 Yiteng Pharmaceutical Recent Developments/Updates
6.11 Beijing Shuoxing Biotechnology
6.11.1 Beijing Shuoxing Biotechnology Company Information
6.11.2 Beijing Shuoxing Biotechnology Description and Business Overview
6.11.3 Beijing Shuoxing Biotechnology Nanobody Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Beijing Shuoxing Biotechnology Nanobody Drug Product Portfolio
6.11.5 Beijing Shuoxing Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nanobody Drug Industry Chain Analysis
7.2 Nanobody Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nanobody Drug Production Mode & Process Analysis
7.4 Nanobody Drug Sales and Marketing
7.4.1 Nanobody Drug Sales Channels
7.4.2 Nanobody Drug Distributors
7.5 Nanobody Drug Customer Analysis
8 Nanobody Drug Market Dynamics
8.1 Nanobody Drug Industry Trends
8.2 Nanobody Drug Market Drivers
8.3 Nanobody Drug Market Challenges
8.4 Nanobody Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Nanobody Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Nanobody Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Nanobody Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Nanobody Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Nanobody Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Nanobody Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Nanobody Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Nanobody Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Nanobody Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Nanobody Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Nanobody Drug, Product Type & Application
Table 12. Global Key Manufacturers of Nanobody Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Nanobody Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanobody Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Nanobody Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Nanobody Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Nanobody Drug Sales Market Share by Region (2020-2025)
Table 19. Global Nanobody Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Nanobody Drug Sales Market Share by Region (2026-2031)
Table 21. Global Nanobody Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Nanobody Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Nanobody Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Nanobody Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Nanobody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Nanobody Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Nanobody Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Nanobody Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Nanobody Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Nanobody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Nanobody Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Nanobody Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Nanobody Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Nanobody Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Nanobody Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Nanobody Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Nanobody Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Nanobody Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Nanobody Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Nanobody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Nanobody Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Nanobody Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Nanobody Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Nanobody Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Nanobody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Nanobody Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Nanobody Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Nanobody Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Nanobody Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Nanobody Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Nanobody Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Nanobody Drug Sales Market Share by Type (2020-2025)
Table 53. Global Nanobody Drug Sales Market Share by Type (2026-2031)
Table 54. Global Nanobody Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Nanobody Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Nanobody Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Nanobody Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Nanobody Drug Price (US$/Unit) by Type (2020-2025)
Table 59. Global Nanobody Drug Price (US$/Unit) by Type (2026-2031)
Table 60. Global Nanobody Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Nanobody Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Nanobody Drug Sales Market Share by Application (2020-2025)
Table 63. Global Nanobody Drug Sales Market Share by Application (2026-2031)
Table 64. Global Nanobody Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Nanobody Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Nanobody Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Nanobody Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Nanobody Drug Price (US$/Unit) by Application (2020-2025)
Table 69. Global Nanobody Drug Price (US$/Unit) by Application (2026-2031)
Table 70. Boehringer Ingelheim Company Information
Table 71. Boehringer Ingelheim Description and Business Overview
Table 72. Boehringer Ingelheim Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Boehringer Ingelheim Nanobody Drug Product
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. Sanofi Company(Ablynx) Company Information
Table 76. Sanofi Company(Ablynx) Description and Business Overview
Table 77. Sanofi Company(Ablynx) Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Sanofi Company(Ablynx) Nanobody Drug Product
Table 79. Sanofi Company(Ablynx) Recent Developments/Updates
Table 80. Merck KGaA Company Information
Table 81. Merck KGaA Description and Business Overview
Table 82. Merck KGaA Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Merck KGaA Nanobody Drug Product
Table 84. Merck KGaA Recent Developments/Updates
Table 85. Jerry Corning Company Information
Table 86. Jerry Corning Description and Business Overview
Table 87. Jerry Corning Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Jerry Corning Nanobody Drug Product
Table 89. Jerry Corning Recent Developments/Updates
Table 90. Shenzhen Pregene Biopharma Co Company Information
Table 91. Shenzhen Pregene Biopharma Co Description and Business Overview
Table 92. Shenzhen Pregene Biopharma Co Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Shenzhen Pregene Biopharma Co Nanobody Drug Product
Table 94. Shenzhen Pregene Biopharma Co Recent Developments/Updates
Table 95. Novamab Company Information
Table 96. Novamab Description and Business Overview
Table 97. Novamab Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Novamab Nanobody Drug Product
Table 99. Novamab Recent Developments/Updates
Table 100. PersonGen Company Information
Table 101. PersonGen Description and Business Overview
Table 102. PersonGen Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. PersonGen Nanobody Drug Product
Table 104. PersonGen Recent Developments/Updates
Table 105. Nanjing Legend Biotechnology Co., Ltd. Company Information
Table 106. Nanjing Legend Biotechnology Co., Ltd. Description and Business Overview
Table 107. Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Product
Table 109. Nanjing Legend Biotechnology Co., Ltd. Recent Developments/Updates
Table 110. Taiwan Taisho Pharmaceutical Company Information
Table 111. Taiwan Taisho Pharmaceutical Description and Business Overview
Table 112. Taiwan Taisho Pharmaceutical Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Taiwan Taisho Pharmaceutical Nanobody Drug Product
Table 114. Taiwan Taisho Pharmaceutical Recent Developments/Updates
Table 115. Yiteng Pharmaceutical Company Information
Table 116. Yiteng Pharmaceutical Description and Business Overview
Table 117. Yiteng Pharmaceutical Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Yiteng Pharmaceutical Nanobody Drug Product
Table 119. Yiteng Pharmaceutical Recent Developments/Updates
Table 120. Beijing Shuoxing Biotechnology Company Information
Table 121. Beijing Shuoxing Biotechnology Description and Business Overview
Table 122. Beijing Shuoxing Biotechnology Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Beijing Shuoxing Biotechnology Nanobody Drug Product
Table 124. Beijing Shuoxing Biotechnology Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Nanobody Drug Distributors List
Table 128. Nanobody Drug Customers List
Table 129. Nanobody Drug Market Trends
Table 130. Nanobody Drug Market Drivers
Table 131. Nanobody Drug Market Challenges
Table 132. Nanobody Drug Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Nanobody Drug
Figure 2. Global Nanobody Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Nanobody Drug Market Share by Type: 2024 & 2031
Figure 4. Monovalent Nanobodies Product Picture
Figure 5. Multivalent Nanobodies Product Picture
Figure 6. Fusion Nanobodies Product Picture
Figure 7. Others Product Picture
Figure 8. Global Nanobody Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Nanobody Drug Market Share by Application: 2024 & 2031
Figure 10. Tumor Treatment
Figure 11. Immune Disease Treatment
Figure 12. Inflammatory Disease Treatment
Figure 13. Others
Figure 14. Global Nanobody Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Nanobody Drug Market Size (2020-2031) & (US$ Million)
Figure 16. Global Nanobody Drug Sales (2020-2031) & (K Units)
Figure 17. Global Nanobody Drug Average Price (US$/Unit) & (2020-2031)
Figure 18. Nanobody Drug Report Years Considered
Figure 19. Nanobody Drug Sales Share by Manufacturers in 2024
Figure 20. Global Nanobody Drug Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Nanobody Drug Players: Market Share by Revenue in Nanobody Drug in 2024
Figure 22. Nanobody Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Nanobody Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Nanobody Drug Sales Market Share by Country (2020-2031)
Figure 25. North America Nanobody Drug Revenue Market Share by Country (2020-2031)
Figure 26. United States Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Nanobody Drug Sales Market Share by Country (2020-2031)
Figure 29. Europe Nanobody Drug Revenue Market Share by Country (2020-2031)
Figure 30. Germany Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Nanobody Drug Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Nanobody Drug Revenue Market Share by Region (2020-2031)
Figure 37. China Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. China Taiwan Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Nanobody Drug Sales Market Share by Country (2020-2031)
Figure 45. Latin America Nanobody Drug Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Colombia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Nanobody Drug Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Nanobody Drug Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Nanobody Drug by Type (2020-2031)
Figure 56. Global Revenue Market Share of Nanobody Drug by Type (2020-2031)
Figure 57. Global Nanobody Drug Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Sales Market Share of Nanobody Drug by Application (2020-2031)
Figure 59. Global Revenue Market Share of Nanobody Drug by Application (2020-2031)
Figure 60. Global Nanobody Drug Price (US$/Unit) by Application (2020-2031)
Figure 61. Nanobody Drug Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Global Nanobody Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Nanobody Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Nanobody Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Nanobody Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Nanobody Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Nanobody Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Nanobody Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Nanobody Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Nanobody Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Nanobody Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Nanobody Drug, Product Type & Application
Table 12. Global Key Manufacturers of Nanobody Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Nanobody Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanobody Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Nanobody Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Nanobody Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Nanobody Drug Sales Market Share by Region (2020-2025)
Table 19. Global Nanobody Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Nanobody Drug Sales Market Share by Region (2026-2031)
Table 21. Global Nanobody Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Nanobody Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Nanobody Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Nanobody Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Nanobody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Nanobody Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Nanobody Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Nanobody Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Nanobody Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Nanobody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Nanobody Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Nanobody Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Nanobody Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Nanobody Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Nanobody Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Nanobody Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Nanobody Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Nanobody Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Nanobody Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Nanobody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Nanobody Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Nanobody Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Nanobody Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Nanobody Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Nanobody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Nanobody Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Nanobody Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Nanobody Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Nanobody Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Nanobody Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Nanobody Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Nanobody Drug Sales Market Share by Type (2020-2025)
Table 53. Global Nanobody Drug Sales Market Share by Type (2026-2031)
Table 54. Global Nanobody Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Nanobody Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Nanobody Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Nanobody Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Nanobody Drug Price (US$/Unit) by Type (2020-2025)
Table 59. Global Nanobody Drug Price (US$/Unit) by Type (2026-2031)
Table 60. Global Nanobody Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Nanobody Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Nanobody Drug Sales Market Share by Application (2020-2025)
Table 63. Global Nanobody Drug Sales Market Share by Application (2026-2031)
Table 64. Global Nanobody Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Nanobody Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Nanobody Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Nanobody Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Nanobody Drug Price (US$/Unit) by Application (2020-2025)
Table 69. Global Nanobody Drug Price (US$/Unit) by Application (2026-2031)
Table 70. Boehringer Ingelheim Company Information
Table 71. Boehringer Ingelheim Description and Business Overview
Table 72. Boehringer Ingelheim Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Boehringer Ingelheim Nanobody Drug Product
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. Sanofi Company(Ablynx) Company Information
Table 76. Sanofi Company(Ablynx) Description and Business Overview
Table 77. Sanofi Company(Ablynx) Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Sanofi Company(Ablynx) Nanobody Drug Product
Table 79. Sanofi Company(Ablynx) Recent Developments/Updates
Table 80. Merck KGaA Company Information
Table 81. Merck KGaA Description and Business Overview
Table 82. Merck KGaA Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Merck KGaA Nanobody Drug Product
Table 84. Merck KGaA Recent Developments/Updates
Table 85. Jerry Corning Company Information
Table 86. Jerry Corning Description and Business Overview
Table 87. Jerry Corning Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Jerry Corning Nanobody Drug Product
Table 89. Jerry Corning Recent Developments/Updates
Table 90. Shenzhen Pregene Biopharma Co Company Information
Table 91. Shenzhen Pregene Biopharma Co Description and Business Overview
Table 92. Shenzhen Pregene Biopharma Co Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Shenzhen Pregene Biopharma Co Nanobody Drug Product
Table 94. Shenzhen Pregene Biopharma Co Recent Developments/Updates
Table 95. Novamab Company Information
Table 96. Novamab Description and Business Overview
Table 97. Novamab Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Novamab Nanobody Drug Product
Table 99. Novamab Recent Developments/Updates
Table 100. PersonGen Company Information
Table 101. PersonGen Description and Business Overview
Table 102. PersonGen Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. PersonGen Nanobody Drug Product
Table 104. PersonGen Recent Developments/Updates
Table 105. Nanjing Legend Biotechnology Co., Ltd. Company Information
Table 106. Nanjing Legend Biotechnology Co., Ltd. Description and Business Overview
Table 107. Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Nanjing Legend Biotechnology Co., Ltd. Nanobody Drug Product
Table 109. Nanjing Legend Biotechnology Co., Ltd. Recent Developments/Updates
Table 110. Taiwan Taisho Pharmaceutical Company Information
Table 111. Taiwan Taisho Pharmaceutical Description and Business Overview
Table 112. Taiwan Taisho Pharmaceutical Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Taiwan Taisho Pharmaceutical Nanobody Drug Product
Table 114. Taiwan Taisho Pharmaceutical Recent Developments/Updates
Table 115. Yiteng Pharmaceutical Company Information
Table 116. Yiteng Pharmaceutical Description and Business Overview
Table 117. Yiteng Pharmaceutical Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Yiteng Pharmaceutical Nanobody Drug Product
Table 119. Yiteng Pharmaceutical Recent Developments/Updates
Table 120. Beijing Shuoxing Biotechnology Company Information
Table 121. Beijing Shuoxing Biotechnology Description and Business Overview
Table 122. Beijing Shuoxing Biotechnology Nanobody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Beijing Shuoxing Biotechnology Nanobody Drug Product
Table 124. Beijing Shuoxing Biotechnology Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Nanobody Drug Distributors List
Table 128. Nanobody Drug Customers List
Table 129. Nanobody Drug Market Trends
Table 130. Nanobody Drug Market Drivers
Table 131. Nanobody Drug Market Challenges
Table 132. Nanobody Drug Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Nanobody Drug
Figure 2. Global Nanobody Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Nanobody Drug Market Share by Type: 2024 & 2031
Figure 4. Monovalent Nanobodies Product Picture
Figure 5. Multivalent Nanobodies Product Picture
Figure 6. Fusion Nanobodies Product Picture
Figure 7. Others Product Picture
Figure 8. Global Nanobody Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Nanobody Drug Market Share by Application: 2024 & 2031
Figure 10. Tumor Treatment
Figure 11. Immune Disease Treatment
Figure 12. Inflammatory Disease Treatment
Figure 13. Others
Figure 14. Global Nanobody Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Nanobody Drug Market Size (2020-2031) & (US$ Million)
Figure 16. Global Nanobody Drug Sales (2020-2031) & (K Units)
Figure 17. Global Nanobody Drug Average Price (US$/Unit) & (2020-2031)
Figure 18. Nanobody Drug Report Years Considered
Figure 19. Nanobody Drug Sales Share by Manufacturers in 2024
Figure 20. Global Nanobody Drug Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Nanobody Drug Players: Market Share by Revenue in Nanobody Drug in 2024
Figure 22. Nanobody Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Nanobody Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Nanobody Drug Sales Market Share by Country (2020-2031)
Figure 25. North America Nanobody Drug Revenue Market Share by Country (2020-2031)
Figure 26. United States Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Nanobody Drug Sales Market Share by Country (2020-2031)
Figure 29. Europe Nanobody Drug Revenue Market Share by Country (2020-2031)
Figure 30. Germany Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Nanobody Drug Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Nanobody Drug Revenue Market Share by Region (2020-2031)
Figure 37. China Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. China Taiwan Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Nanobody Drug Sales Market Share by Country (2020-2031)
Figure 45. Latin America Nanobody Drug Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Colombia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Nanobody Drug Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Nanobody Drug Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Nanobody Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Nanobody Drug by Type (2020-2031)
Figure 56. Global Revenue Market Share of Nanobody Drug by Type (2020-2031)
Figure 57. Global Nanobody Drug Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Sales Market Share of Nanobody Drug by Application (2020-2031)
Figure 59. Global Revenue Market Share of Nanobody Drug by Application (2020-2031)
Figure 60. Global Nanobody Drug Price (US$/Unit) by Application (2020-2031)
Figure 61. Nanobody Drug Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global LED Light Housing Market Research Report 2025
Sep 24, 25
Global Side Emitting LED Strip Light Market Research Report 2025
Sep 24, 25
Global Medium and Low Voltage Unshielded Cable Market Research Report 2025
Sep 24, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232